VALYSTR · Stock research
Listed on Korea Exchange. What the market is pricing into Samsung Biologics (207940.KS) in the Healthcare sector: implied growth, valuation scenarios, SEC-filed financials, and what has moved the stock.
Healthcare · Biotechnology · P/E 36.6 (as of 2026-11-04)
Opening the full page… All companies · Research guides · What a reverse DCF shows